Therapeutic diminution of Interleukin-10 with intranasal theophylline administration in hyposmic patients

Am J Otolaryngol. 2022 Mar-Apr;43(2):103375. doi: 10.1016/j.amjoto.2022.103375. Epub 2022 Jan 28.

Abstract

Objective: To determine changes in nasal mucus Interleukin-10 (IL-10) before and after intranasal theophylline treatment in hyposmic patients, and the relationship of these changes to orally administered theophylline treatment.

Design: IL-10 was measured in nasal mucus samples of 17 normal subjects and 39 patients with hyposmia of multiple etiologies by use of a sensitive spectrophotometric ELISA assay. Hyposmia is defined clinically by standardized evaluation of impaired olfactometry, as well as subjectively self reported by the patient.

Results: Prior to treatment, IL-10 levels in nasal mucus were increased in hyposmic patients compared to controls. Following intranasal theophylline administration, over half of treated patients experienced a decrease of nasal mucus IL-10 toward control levels, correlated with a significant improvement in taste and smell function. Patients who increased with intranasal administration, similar to previously reported oral administration, showed no significant improvement in taste or smell function.

Conclusions: Nasal mucus IL-10 decreased in patients treated with intranasal theophylline. Mechanisms of action include phosphodiesterase and nuclear factor kappa-B inhibition, correlated with an improvement in both olfaction and gustation. IL-10 is induced by therapeutic and systemic administration of theophylline as with oral dosage, but reduced by lower and localized treatment.

Keywords: Hypogeusia; Hyposmia; IL-10; Inflammation; Interleukin-10; Nasal mucus; Nasal secretion; Theophylline.

MeSH terms

  • Administration, Intranasal
  • Humans
  • Interleukin-10
  • Olfaction Disorders* / drug therapy
  • Olfaction Disorders* / etiology
  • Smell
  • Theophylline* / therapeutic use

Substances

  • Interleukin-10
  • Theophylline